Literature DB >> 19357348

Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells.

Emanuela Matteucci1, Paola Bendinelli, Maria Alfonsina Desiderio.   

Abstract

Hepatocyte growth factor (HGF)/Met system is deregulated in tumors and is implicated in different aspects of invasive growth. Here, we report that in the highly aggressive MDA-MB231 breast carcinoma cells, Met cytosolic fragments [C-terminal fragment (CTF)] were present in the nuclei. They were constitutively active because tyrosine phosphorylated at regulatory and catalytic domains and endowed with transactivating activity independently of HGF exposure. In fact, various constructs containing juxtamembrane (Jxtm) Met fragments, fused with Gal4 DNA-binding domain, transactivated Gal4Luc activity. MDA-MB231 cells were devoid of WW domain-containing oxidoreductase (Wwox) tumor suppressor. Exogenous Wwox protein expression negatively regulated Jxtm3-transactivating activity and decreased spontaneous migration of MDA-MB231 cells. Also, we demonstrate that the lack of endogenous Wwox in MDA-MB231 cells represented a molecular mechanism for intranuclear Met-CTF accumulation and for the decrease of full-length Met stability. Yes-associated proteins maintained constitutively activated nuclear Met fragments that played a role as transcription factors regulating genes probably including those for motile phenotype. The difference with low invasive MCF-7 cells was evident because the latter did not show intranuclear Met and the transfected constructs-containing Jxtm fragments were inactive also in the presence of HGF. The constitutive activation of nuclear Met-signaling pathway in MDA-MB231 cells, possibly determined at genetic or epigenetic levels of WWOX gene, might participate in breast carcinoma progression influencing invasive/metastatic phenotype. Wwox/Met system can be suggested as a potential target to impair breast carcinoma progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357348     DOI: 10.1093/carcin/bgp080

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  42 in total

1.  Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells.

Authors:  Tiannan Guo; Yi Zhu; Chee Sian Gan; Sze Sing Lee; Jiang Zhu; Haixia Wang; Xin Li; James Christensen; Shiang Huang; Oi Lian Kon; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2010-08-16       Impact factor: 5.911

2.  H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism.

Authors:  Mei-Kuang Chen; Yi Du; Linlin Sun; Jennifer L Hsu; Yu-Han Wang; Yuan Gao; Jiaxing Huang; Mien-Chie Hung
Journal:  J Biol Chem       Date:  2019-04-08       Impact factor: 5.157

Review 3.  Phosphorylation/de-phosphorylation in specific sites of tumor suppressor WWOX and control of distinct biological events.

Authors:  Shenq-Shyang Huang; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-08

Review 4.  Targeting the HGF/Met signaling pathway in cancer therapy.

Authors:  Fabiola Cecchi; Danie C Rabe; Donald P Bottaro
Journal:  Expert Opin Ther Targets       Date:  2012-04-25       Impact factor: 6.902

5.  Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.

Authors:  Mireia Náger; Maria Santacana; Deepshikha Bhardwaj; Joan Valls; Isidre Ferrer; Pere Nogués; Carles Cantí; Judit Herreros
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Expression of the c-Met Proteins in Malignant Skin Cancers.

Authors:  Yoon-Jin Lee; Dae-Hyun Kim; Sang-Han Lee; Dong-Wook Kim; Hae-Seon Nam; Moon Kyun Cho
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

7.  Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation.

Authors:  Sandra Vorlová; Gina Rocco; Clare V Lefave; Francine M Jodelka; Ken Hess; Michelle L Hastings; Erik Henke; Luca Cartegni
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

Review 8.  WWOX gene and gene product: tumor suppression through specific protein interactions.

Authors:  Zaidoun Salah; Rami Aqeilan; Kay Huebner
Journal:  Future Oncol       Date:  2010-02       Impact factor: 3.404

9.  Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Authors:  Yong Qin; Jason Roszik; Chandrani Chattopadhyay; Yuuri Hashimoto; Chengwen Liu; Zachary A Cooper; Jennifer A Wargo; Patrick Hwu; Suhendan Ekmekcioglu; Elizabeth A Grimm
Journal:  Mol Cancer Ther       Date:  2016-07-25       Impact factor: 6.261

10.  Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene.

Authors:  John H Ludes-Meyers; Hyunsuk Kil; Jan Parker-Thornburg; Donna F Kusewitt; Mark T Bedford; C Marcelo Aldaz
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.